Stream
Stories
-
Hoffmann-La Roche posts results of Phase 3 IMpower030 atezolizumab trial in resectable NSCLC
Results for the IMpower030 study were first posted on ClinicalTrials.gov on October 9, 2026. The Phase 3 trial enrolled 453 participants and completed primary data collection on October 1, 2025.
-
Hoffmann-La Roche posts results of Phase 3 alectinib rollover study
Results for the study were first posted on ClinicalTrials.gov on October 9, 2026. The completed Phase 3 rollover study enrolled 50 participants and compared alectinib with crizotinib in patients with ALK- or RET-positive cancer.
-
Sanofi posts results of Phase 3 Itepekimab trial in COPD
The study, NCT04751487 (AERIFY-2), enrolled 1234 participants and completed in April 2025. It evaluated itepekimab versus placebo on exacerbation rates, pulmonary function, and safety in moderate-to-severe COPD patients.
-
FDA corrects withdrawal notice of 16 ANDAs
The FDA issued a correction to a June 3, 2026 notice that announced the withdrawal of approval of 16 abbreviated new drug applications, effective July 6, 2026. The correction removes entries for ANDA 207366, ANDA 212957, and ANDA 218638, noting that Navinta LLC requested the approvals not be withdrawn, so those approvals remain in effect.
-
FDA withdraws approval of Amneal's celecoxib ANDA
FDA withdraws approval of abbreviated new drug application 208833 for celecoxib capsules 50 mg, 100 mg, 200 mg, and 400 mg held by Amneal Pharmaceuticals of New York, LLC. Amneal requested the withdrawal and waived its opportunity for a hearing.
-
FDA withdraws approval of 37 ANDAs
The agency is withdrawing approval of 37 abbreviated new drug applications from multiple applicants. The applicants notified the FDA that the drug products were no longer marketed and requested the approvals be withdrawn.
-
FDA issues priority review voucher for ZANVASTRO
FDA approved ZANVASTRO on September 3, 2026. FDA issued a priority review voucher to the sponsor, Ionis Pharmaceuticals, Inc., after determining the product meets the criteria under the FD&C Act.
-
FDA classifies hematopoietic cell enrichment kit as class II device
The order designates the kit as a class II device with special controls. The special controls will be part of the codified language for classification of the hematopoietic cell enrichment kit.
-
FDA classifies infant pulse rate and oxygen saturation monitor as class II
The order assigns the device to class II, adding special controls to the codified language. The action is expected to enhance patients' access to beneficial innovative devices by reducing regulatory burdens.
-
CMS releases 2027 Medicare Advantage and Part D Star Ratings
The Centers for Medicare & Medicaid Services published the 2027 Star Ratings on October 8, 2026, and the ratings will impact 2028 MA quality bonus payments. Approximately 37% of MA-PD contracts (188 contracts) earned four stars or higher, and 27% of PDPs (11 contracts) received four or more stars for 2027.
-
FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq, Genentech, Inc.) with fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The approval also covers atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for patients 12 years and older who weigh 40 kg or greater.
-
Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes
The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.